AbbVie (ABBV) : Fridays money flow indicated an uptick to downtick ratio was at 1.26. The total value of inflow transactions on upticks was $38.67 million, whereas, the total value of outflow trades on downticks was $30.57 million. The total money flow was $8.1 million, which shows a mild bullish bias. The total money flow into the stock in block trades was $7.72 million. The total value of the trades done on upticks was $10.38 million. Downticks saw transactions worth $2.66 million. The total uptick to downtick ratio stood at 3.9, mildly in favor of the bulls. AbbVie (ABBV) was trading with a -0.2% change over previous days close. It fell $0.13 during the day and reached $63.91. The stock was -1.09% compared to the previous weeks close.
The company Insiders own 0.11% of AbbVie shares according to the proxy statements. Institutional Investors own 68.57% of AbbVie shares. During last six month period, the net percent change held by insiders has seen a change of -16.87%.
In a related news, Schumacher Laura J, Officer (Executive Vice President) of AbbVie Inc., unloaded 186,106 shares at an average price of $60.07 on June 24, 2016. The total amount of the transaction was worth $11,179,387, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
AbbVie (NYSE:ABBV): The stock opened at $64.37 and touched an intraday high of $64.48 on Friday. During the day, the stock corrected to an intraday low of $63.8737, however, the bulls stepped in and pushed the price higher to close in the green at $64.12 with a gain of 0.14% for the day. The total traded volume for the day was 4,100,767. The stock had closed at $64.03 in the previous trading session.
AbbVie (ABBV) : During the past 4 weeks, traders have been relatively bearish on AbbVie (ABBV), hence the stock is down -3.51% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -1.26% relative to the S&P 500. The 4-week change in the price of the stock is -3.64% and the stock has fallen -0.76% in the past 1 week.
AbbVie Inc. (AbbVie) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Companys products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohns disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinsons disease; complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. AbbVie also has a pipeline of new medicines, including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties, such as immunology, virology/liver disease, oncology, renal disease, neurological diseases and womens health. The Companys product portfolio includes HUMIRA, HCV products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.